Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21511099 | 0.80 | ENPP2 (0.42) | ENPP2ALDH1A1ALOX15HSD17B10KCNH2 | |
| SCHEMBL22668555 | 0.80 | ENPP2 (0.42) | ENPP2ALDH1A1ALOX15HSD17B10KCNH2 | |
| SCHEMBL6197480 | 0.80 | ENPP2 (0.50) | ENPP2ALDH1A1ALOX15HSD17B10TDP1 | |
| SCHEMBL14666985 | 0.78 | KDM4E (0.48) | ENPP2TDP1KCNH2KCNJ1MAPT | |
| SCHEMBL21555231 | 0.77 | NPC1 (0.33) | ENPP2ALDH1A1ALOX15HSD17B10SCN10A | |
| SCHEMBL23118240 | 0.75 | SCN10A (0.47) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL2707266 | 0.75 | SCN10A (0.47) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL26223327 | 0.72 | ENPP2 (0.39) | ENPP2ALDH1A1ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL21577654 | 0.71 | CNR2 (0.35) | ENPP2ALDH1A1ALOX15HSD17B10KCNH2 | |
| SCHEMBL761268 | 0.71 | ALDH1A1 (0.42) | ALDH1A1ALOX15HSD17B10HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-06-22 | — | — | US | disclosed |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-06-22 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| US-20220143059-A1 | COMPOSITIONS AND THERAPEUTIC METHODS | AYUVIS RESEARCH, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11207343-B2 | Compositions and therapeutic methods | AYUVIS RESEARCH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210347742-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | ENPP2 1244/4885ALDH1A1 4725/4885ALOX15 2761/4885 |
| US-11207343-B2 | Compositions and therapeutic methods | RB1, TNF, FLT1 | ENPP2 232/4885ALDH1A1 2410/4885ALOX15 793/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ENPP2 63/4885ALDH1A1 4701/4885ALOX15 3974/4885 |
| US-20220143059-A1 | COMPOSITIONS AND THERAPEUTIC METHODS | RB1, FLT1, FLT4 | ENPP2 332/4885ALDH1A1 2737/4885ALOX15 935/4885 |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | PIGS, NAT1, AADAC | ENPP2 692/4885ALDH1A1 176/4885ALOX15 896/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ENPP2 63/4885ALDH1A1 4701/4885ALOX15 3974/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | ENPP2 254/4885ALDH1A1 778/4885ALOX15 3571/4885 |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ENPP2 478/4885ALDH1A1 3939/4885ALOX15 2899/4885 |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | ENPP2 1679/4885ALDH1A1 3625/4885ALOX15 3847/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ENPP2 478/4885ALDH1A1 3939/4885ALOX15 2899/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ENPP2 478/4885ALDH1A1 3939/4885ALOX15 2899/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | ENPP2 15/4885ALDH1A1 3199/4885ALOX15 2197/4885 |
| US-20210347742-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | ENPP2 171/4885ALDH1A1 2135/4885ALOX15 1031/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | ENPP2 176/4885ALDH1A1 1567/4885ALOX15 1552/4885 |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | CACNA1B, CACNG3, CACNA1C | ENPP2 2937/4885ALDH1A1 3348/4885ALOX15 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.